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Introduction:We investigatedwhether life-course factors and neuroimaging biomark-
ers of Alzheimer’s disease pathology predict reaction time (RT) performance in older
adults.
Methods: Insight 46 study participants, all born in the same week in 1946 (n = 501;
ages at assessment = 69 to 71 years), completed a 2-choice RT task and amyloid
beta (Aβ) positron emission tomography and MR imaging. We tested for associations
between task outcomes (RT; error rate; intra-individual variability in RT) and life-
course predictors including childhood cognitive ability and education. In a subsample
of 406 cognitively normal participants, we investigated associations between task out-
comes and biomarkers including Aβ-positivity.
Results: Cognitively normal Aβ-positive participants had 10% more variable RTs than
Aβ-negative participants, despite having similar mean RTs. Childhood cognitive ability
and education independently predicted task performance.
Discussion: This study provides novel evidence that Aβ pathology is associated with
poorer consistency of RT in cognitively normal older adults, at an age when dementia
prevalence is still very low.
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1 BACKGROUND
Many cognitively normal older adults show biomarker evidence of
accumulating brain pathologies in an age-related manner, with a
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significant proportion meeting criteria for preclinical Alzheimer’s dis-
ease (AD).1,2 As the preclinical stage of AD extends up to around 20
years before the onset of symptoms,3,4 and many individuals meeting
the biomarker criteria may never develop cognitive impairment within
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their lifetimes,5 it is important to understand the relationship between
preclinical pathology and cognitive decline. While there is evidence
that subtle cognitive decline is detectable in older adults with preclini-
cal AD,6-8 questions remain about the nature and timing of the earliest
cognitive changes and how theymay be disentangled from age-related
cognitive decline. Answering thesequestionswould improveour ability
to identify individuals at highest risk of cognitive impairment, as well
as informing the selection of sensitive cognitive measures for clinical
trials.
Throughout adulthood, reaction time (RT) becomes notably slower
and less consistent (ie, intra-individual variability [IIV] increases).9-15
Patients with AD are reported to have slower RTs and greater IIV
than controls,15-18 with a similar pattern observed in mild cogni-
tive impairment (MCI).16,19-22 Choice reaction time (CRT, requiring
selection of the correct response from two or more options) may
be particularly informative because—compared to simple RT—it is
more sensitive to age and cerebral dysfunction.10,13 To our knowl-
edge, no studies have investigated associations between CRT per-
formance (RT, IIV, and error rate) and biomarkers of AD pathology
in cognitively normal older adults. There is some evidence that indi-
viduals meeting criteria for preclinical AD are subtly impaired on
paper-and-pencil measures of processing speed (eg, Baker et al. 6
and Ho and Nation8), but such tests do not allow measurement of
IIV.
If subtle cognitive decline in the preclinical phase of AD is to be
detected, it is important to account for other factors that may con-
tribute to inter-individual differences, such as sex and prior cogni-
tive ability. Evidence for sex differences in RT is mixed,10,11,16,19,23
whereas associations betweenRT and general cognitive ability arewell
established.9,24-27 While CRT experiments typically consider RT sep-
arately from error rate, it may also be important to consider speed-
accuracy trade-offs.
Insight 46, a substudyof theNational SurveyofHealth andDevelop-
ment (NSHD, the British 1946 Birth Cohort), provides a unique oppor-
tunity to study preclinical AD. Participants are drawn from the world’s
longest continuously running birth cohort study, with life-course data
available on their cognition since childhood as well as a wealth of
sociodemographic, health, and lifestyle factors.28 They were assessed
at age ≈70 years, when the prevalence of dementia is low (≈3%)29 but
the prevalence of amyloid beta (Aβ) pathology is already around 15%
to 25%.2,30 We recently reported that cognitively normal Aβ-positive
participants scored slightly lower than Aβ-negative participants on
standard paper-and-pencil measures of episodic memory, processing
speed, and non-verbal reasoning.31 Wenow report the results of a CRT
task.
The aims of this study were to: (1) describe performance on
a CRT task and its associations with demographic and life-course
predictors; and (2) investigate associations between task perfor-
mance and biomarkers of brain pathologies among cognitively nor-
mal participants. Our key hypothesis was that Aβ-positive partic-
ipants would have slower RTs and greater IIV than Aβ-negative
participants.
HIGHLIGHTS
∙ Participants (n = 501) were all born in the same week in
March 1946.
∙ Assessments at age ∼70 included a choice reaction time
test and amyloid-PET/MRI.
∙ Amyloid pathology was associated with greater variability
in reaction time.
∙ Reaction time variability may be a sensitive measure of
subtle cognitive decline.
RESEARCH INCONTEXT
1. Systematic review: The authors reviewed the literature
using traditional sources (eg, PubMed).While there is evi-
dence that subtle cognitive decline is detectable during
the preclinical stage of Alzheimer’s disease, the nature of
changes in reaction time has received little attention.
2. Interpretation: In a sample of British adults all born dur-
ing the sameweek in 1946, cognitively normal individuals
with amyloid beta (Aβ) pathology were less consistent in
their response times on a choice reaction time (CRT) task,
although their responses were not slower overall. This
builds on previous evidence that Aβ pathology is associ-
atedwith subtle changes inmultiple cognitivedomains (ie,
not just memory) by age 70.
3. Future Directions: Continued follow-up of these partici-
pants will be important to examine how changes in CRT
relate to accumulatingpathologies. Further studieswould
bebeneficial to examine thepotential ofCRT tasks as sen-
sitive measures of subtle cognitive decline for clinical tri-
als.
2 METHODS
The NSHD is a population-based sample originally consisting of 5362
individuals born across mainland Britain during one week in March
1946, who have been assessed 24 times across the lifespan.28 Recruit-
ment procedures, assessment protocols, and recruitment flow-charts
for the Insight 46 substudy have been previously published.31-34 In
brief, 502 individuals attended University College London between
May 2015 and January 2018 and underwent cognitive tests, clini-
cal examination, brain magnetic resonance imaging (MRI), Aβ-positron
emission tomography (PET), and other biomarker measures. The study
was approved by the National Research Ethics Service Committee
London (REC reference 14/LO/1173). Participants provided written
informed consent.
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F IGURE 1 The choice reaction time task. The cue (“Arrow" in
Block 1; “Word" in Block 2) appeared on its own for 1000ms before
the stimulus appeared underneath. The XXX inside the arrow is not
relevant for the response, but was included so that the appearance
and visual complexity of both blocks were as similar as possible
2.1 CRT task
2.1.1 Procedure
The CRT task was inspired by previous experiments.35,36 Stimuli were
presented on a DELL Optiplex 9030 computer, using SuperLab soft-
ware. ACedrusRB-740 responseboxwith twobuttons side by sidewas
placed in front of the participant. The experiment had two blocks: in
block 1 the stimulus was an arrow pointing left or right; in block 2 the
stimuluswas theword ‘LEFT’ or ‘RIGHT’ (Figure 1). All stimuli were dis-
played in the center of the screen.
Each block contained 12 trials in a fixed order (Block 1: LRRRLRL-
RLLRL; Block 2: LLLLRRRLRRRL). To pace the experiment, each trial
began with a cue displayed for 1000 ms (“Arrow" in Block 1; “Word"
in Block 2), before the stimulus appeared. Six practice trials preceded
each block.
Participants were instructed to press the correct button (left or
right) as quickly as possible, using the index and middle fingers of their
dominant hand. If their response was correct, the next trial was initi-
ated; if incorrect, the stimulus remained on the screen and an error
tone signaled that they should respond again. Regardless of whether
their second attempt was correct or incorrect, no feedback was given
and the next trial was initiated.
Two variables were recorded for each response: RT (ms) and accu-
racy (correct or incorrect). The total time to complete the task—
including explaining the instructions and completing the practice—was
extracted from the output.
2.1.2 Data processing
During testing it was observed that participantswere not always ready
for the first trial of each block, so these trials were dropped from anal-
ysis. All analyses were based on the initial response to each stimulus;
second attempts were not analyzed as their purpose was to reorient
participants to the task. As the highest error rate was 27% (Table 1),
no participants were excluded based on responding at random. RTs
were checked for outliers. As in a previous study,35 a threshold of 300
ms was adopted as the minimum time for a valid response, although
in fact no responses were faster than this. A threshold of three stan-
dard deviations (SD) above each participant’s own mean was used to
exclude outlying slow responses,12,37 resulting in the exclusion of 0.4%
of responses from the RT analyses.
2.2 Life-course and clinical variables
Childhood cognitive ability was measured at age 8 (or ages 11 or 15 if
earlier data were missing) as a standardized z-score based on tests of
verbal and non-verbal ability, as previously described.31
Educational attainment was represented as the highest qualifica-
tion achieved by age 26, grouped into five categories: no qualifica-
tion, belowO-levels (vocational),O-levels andequivalents, A-levels and
equivalents, higher education (degree and equivalents).
Socioeconomic position was derived from participants’ own occu-
pation at age 53, or earlier if this was missing, coded in six cate-
gories according to the UK Registrar General’s Standard’s Occupa-
tional Classification: unskilled, partially skilled, skilled manual, skilled
non-manual, intermediate, professional.
Participants were classified as having a neurological or psychiatric
condition (including dementia andMCI) as previously described.31 Par-
ticipants not meeting these criteria are hereafter referred to as cogni-
tively normal and represent a sample free from possible confounding
comorbidities.
2.3 Biomarker measures
As previously described,32,34,38 Aβ-PET and multi-modal MRI data
were collected simultaneously during a 60-minute scanning session
on a single Biograph mMR 3T PET/MRI scanner (Siemens Healthcare,
Erlangen), with intravenous injection of 370 MBq of 18F-Florbetapir
(Amyvid). Aβ deposition was quantified using the standard uptake vol-
ume ratio (SUVR) calculated from cortical regions of interest. A cut-
point for Aβ-positivity was determined at SUVR>0.6104.31,34,38
Whole brain volume was generated from high resolution 3D T1-
weighted MRI using automated segmentation with manual editing.32
Total intracranial volume (TIV) was generated using statistical para-
metric mapping software (SPM12; http://www.fil.ion.ucl.ac.uk/spm).32
Global white matter hyperintensity volume (WMHV) was generated
using an automated segmentation algorithm followed by visual quality
control.31,34
Apolipoprotein E (APOE) genotype was classified as ε4-carrier or
non-carrier.32
2.4 Participants
Out of the 502 participants, 501 completed the CRT task. Of
these, there were 406 cognitively normal participants with complete
biomarker data, of whom 18% were Aβ-positive31,34 Of note, three
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TABLE 1 Participant characteristics and descriptive statistics for the choice reaction time task (n= 501)
Cognitively normal
a
participants with complete biomarker
data (n= 406)
b
All participants Aβ positive Aβ negative
N 501 74 332
Sex: % female 49 46 51




70.7, 0.68 (69.2 to 71.8) 70.6, 0.66 (69.4 to 71.8) 70.6, 0.70 (69.2 to 71.8)
Highest educational qualification: %
None 15.6 17.6 15.4
BelowO-levels (vocational) 5.2 6.8 4.2
O-levels or equivalent 24.8 25.7 26.2
A-levels or equivalent 35.7 32.4 35.2
Degree or equivalent 18.8 17.6 19.0




0.39, 0.74 (−1.60 to 2.50) 0.44, 0.74 (−1.37, 2.50) 0.41, 0.74 (−1.59 to 2.47)
Socioeconomic position: %
Unskilled 1.0 1.4 0.6
Partially skilled 4.8 2.7 5.4
Skilledmanual 9.4 9.5 9.3
Skilled non-manual 21.2 16.2 22.0
Intermediate 52.3 55.4 51.8
Professional 11.4 14.9 10.8
MMSE score (max. 30): median, IQR,
(range)
30, 30 to 30 (22 to 30) 29, 29 to 30 (26 to 30) 30, 30 to 30 (26 to 30)
Standard uptake volume ratio: median,
IQR, (range)
0.55, 0.51 to 0.58 (0.45 to 0.87)
e
0.67, 0.64 to 0.71 (0.61 to 0.87) 0.53, 0.51 to 0.56 (0.47 to 0.61)
Whitematter hyperintensity volume
(cm3): median, IQR, (range)
3.1, 1.6 to 6.8 (0.3 to 33.7)
f
3.3, 1.8 to 6.8 (0.3 to 33.7) 2.9, 1.5 to 6.4 (0.3 to 32.8)
Whole brain volume (cm3): mean, SD,
(range)
1100, 99 (819 to 1494)
g
1118, 103 (819 to 1326) 1098, 97 (860 to 1494)
APOE genotype: %
h
ε4-carrier 29.7 60.8 22.9
Non-carrier 70.3 39.2 77.1
Choice reaction time outcomes (unadjusted):
RT (ms): mean, SD, (range) 781, 80, (615 to 1234) 787, 76, (615 to 1012) 778, 78, (623 to 1234)
Error rate (%): median, IQR, (range) 0, 0 to 4.5, (0 to 22.7) 0, 0 to 4.5, (0 to 18.2) 0, 0 to 4.5, (0 to 18.2)
Intra-individual variability in RT:
mean, SD, (range)
0.125, 0.034, (0.043 to 0.231) 0.133, 0.034, (0.043 to 0.201) 0.123, 0.033, (0.047 to 0.231)
Abbreviation: Aβ, amyloid beta; APOE, apolipoprotein E; IQR, interquartile range; MMSE, Mini-Mental State Examination; RT, reaction time; SD, standard
deviation.
aSee section 2.2 and Lu et al.31 for definition.
bχ2, t tests, and rank-sum tests were used to test for differences between the Aβ-positive and -negative groups for the demographic, biomarker, and clinical
variables; the only variable with a statistically significant difference was APOE (P< 0.0001).
cAge at assessment was calculated based on the date that the cognitive assessment was carried out (while assessments were typically completed on one day,
62 participants had to have their scans rescheduled for a later date, with amedian interval of 49 days [range 1 to 216 days]).
dZ-scores for childhood cognitive ability were based on the full National Survey of Health and Development cohort of N = 5362, so the mean for Insight 46
participants indicates that they had higher childhood cognitive ability on average than their peers not recruited to this substudy.
en= 461 due tomissing data.
fn= 454 due tomissing data.
gn= 467 due tomissing data.
hn= 500 due tomissing data.
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participants had dementia and eleven met criteria for MCI. Participant
characteristics are reported in Table 1.
2.5 Data analyses
Themain analyseswereperformedusing summary scores, as described
below. See supporting information for analyses performed using trial-
by-trial data, including comparison of arrow versus word stimuli,
consideration of practice effects, and investigation of within-subject
speed-accuracy trade-offs. We combined outcomes across the two
blocks as the magnitude of differences in RT and error rate between
the two stimulus types was small (supporting information). Three
outcomes were generated:
1. Mean RT for correct responses
2. Error rate (% incorrect responses)
3. Intra-individual variability in RT (IIV) for correct responses, defined
as SD/mean. This “coefficient of variation" is a commonly used
measure that accounts for an individual’s average RT (eg, Der and
Deary10 and Hultsch et al.17), as variability is a function of overall
response speed. The supporting information includes an illustration
of IIV.
Two sets of analyses were conducted. To investigate demographic
and life-course predictors of performance on each outcome, all 501
participants were included to have as representative a sample as pos-
sible. Regression models were fitted (details below), with predictors of
sex, age at assessment, childhood cognitive ability, education, socioeco-
nomic position, and presence of a neurological or psychiatric condition
(yes or no).
To investigate associations between task performance andbiomark-
ers of brain pathologies, analyses only included participants classified
as cognitively normal, and for whom complete biomarker data were
available (n= 406). Regressionmodels were fitted (details below), with
predictors of amyloid status (positive or negative), whole brain vol-
ume, WMHV, and APOE genotype (ε4-carrier or non-carrier), in addi-
tion to the demographic and life-course predictors included previously
(sex, age at assessment, childhood cognitive ability, education, socioe-
conomic position). To adjust for the correlation between brain volumes
and head size, TIV was also included as a covariate. Supplementary
analyses were conducted to test whether SUVR was associated with
differences in performance (see supporting information).
Mean RT was analyzed using a linear regression model. As a log-
transformation did not remove the skew, untransformed data were
used for ease of interpretation, but bootstrappingwas used to produce
bias-corrected and accelerated 99%, 95%, and 90% confidence inter-
vals (CIs)from2000 replications. Error ratewas analyzedusing a gener-
alized estimating equations logistic regression model with an indepen-
dentworking correlation structure and robust standard errors to allow
for correlation between repeated responses by the same participant.
IIV was approximately normally distributed and was analyzed using a
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F IGURE 2 Error rate against mean reaction time (RT), showing
speed-accuracy trade-off (n= 501)
by testing for Spearman’s rank correlation betweenmean RT and error
rate. All analyses were conducted using Stata-15 (StataCorp). Statisti-
cal significance was set at P< 0.05.
3 RESULTS
The median duration of the task was 2.2 minutes (inter-quartile range
= 2.0 to 2.4). Descriptive statistics for CRT outcomes are reported in
Table 1.
3.1 Speed-accuracy trade-offs
Slower mean RT was associated with lower error rate, indicating a
speed-accuracy trade-off (Spearman’s ρ=−0.28, P< 0.0001; Figure 2).
The correlation was weak due to a ceiling effect on accuracy. How-
ever, all of the participants with the highest error rates had relatively
fastmeanRTs, and all of the slowest-responding participantsmade few
errors.
3.2 Demographic and life-course predictors
Results of the multivariable regression models are reported in
Table 2.
Older age at assessment was associatedwith slower RT, lower error
rate, and greater IIV.
Higher childhood cognitive abilitywas associatedwith faster RT and
lower error rate, but did not show evidence of a statistically significant
association with IIV.
Education was not associated with RT or error rate, but higher
educational attainment was associated with slightly reduced IIV
(equivalent to a 9.0% reduction between the lowest and highest
categories of educational qualification [see section 2.2]).
Participantswith neurological andpsychiatric conditions did not dif-
fer from cognitively normal participants in terms of mean RT, but made
more errors (adjusted mean error rates: 3.8% vs 2.5%) and had 12.0%
greater IIV (adjustedmeans: 0.139 vs 0.124).
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TABLE 2 Associations between demographic and life-course predictors and choice reaction time outcomes (n= 501)
Predictor RT (ms): coefficient and 95%CIs
Odds ratio formaking an error
and 95%CIs
Intra-individual variability in RT:
coefficient and 95%CIs
Sex (female as reference) −8.5 (−22.9, 7.8) 1.11 (0.85, 1.45) −0.0050 (−0.0109, 0.0010)
Age at assessment (per year) 24.0*,† (14.7, 35.4) 0.81* (0.68, 0.98) 0.0085*,† (0.0043, 0.0128)
Childhood cognitive ability (per
z-score)
−11.6* (−23.2,−0.08) 0.73*,† (0.60, 0.89) −0.0036 (−0.0082, 0.0009)
Education (per category)
‡









9.5 (−13.2, 40.3) 1.58*† (1.14, 2.19) 0.0149*† (0.0050, 0.0247)
Abbreviations: CI, confidence interval; IIV, intra-individual variability; RT, reaction time.
*Significant at P< 0.05.
†Significant at P< 0.01.
‡See section 2.2 for definitions.
Positive coefficients on RT reflect slower responses; odds ratios >1 for errors reflect higher error rates; positive coefficients on IIV reflect more variable
responses. Multivariable regressionmodels were used so each association is independent of all others.
TABLE 3 Associations between biomarkers and choice reaction time outcomes in cognitively normal participants (n= 406)
Predictor
Mean RT (ms): coefficient (95%
CIs)
Odds ratio formaking an error
(95%CIs)
Intra-individual variability in RT:
coefficient (95%CIs)
Aβ status (negative as reference) 11.7 (−7.8, 30.8) 1.37 (0.93, 2.01) 0.013*† (0.004, 0.021)
WMHV (per 10mL) −3.9 (−15.1, 7.6) 0.90 (0.69, 1.17) −0.003 (−0.008, 0.003)
Whole brain volume (per 10mL) −1.7 (−3.6, 0.1) 1.01 (0.97, 1.04) −0.000 (−0.001, 0.000)
APOE-ε4 (non-carriers as reference) −2.2 (−18.0, 14.8) 0.94 (0.68, 1.30) −0.004 (−0.011, 0.003)
Abbreviations: Aβ, amyloid beta; CI, confidence interval; IIV, intra-individual variability; RT, reaction time;WMHV, whitematter hyperintensity volume.
*Significant at P< 0.05.
†Significant at P< 0.01.
Positive coefficients on RT reflect slower responses; odds ratios >1 for errors reflect higher error rates; positive coefficients on IIV reflect more variable
responses. Multivariable regression models were used so each association is independent of all others. In addition to the predictors listed, models also
included sex, age at assessment, childhood cognitive ability, socioeconomic position, and total intracranial volume, but these associations are not reported
as they are essentially unchanged from the first analysis (see Table 2).
There was no evidence of sex differences on any outcome, nor any
associations with socioeconomic position.
3.3 Associations with biomarkers
Results of themultivariable regressionmodels are reported in Table 3.
Aβ-positive participants had 10.3% greater IIV than Aβ-negative
participants (adjusted means: 0.135 vs 0.122; Figure 3)—despite hav-
ing similar mean RTs (see also Table 1). Aβ-positive participants also
had slightly higher error rates, but this difference was not statisti-
cally significant. Given the evidence that performance was influenced
by speed-accuracy trade-offs, we conducted a post-hoc analysis to
investigate whether Aβ-positive and -negative participants differed in
their error rates after accounting for their overall response speed. The
regression model for error rate was rerun with mean RT as an addi-
tional covariate, and results indicated that Aβ-positive participants had
higher odds of making an error after adjustment for their mean RTs
(odds ratio [OR] = 1.48, 95% CI: 1.03 to 2.14, P = 0.03; adjusted mean
error rates: Aβ-positive= 3.3%; Aβ-negative= 2.3%ms).
When dichotomous amyloid status was replaced with continuous
SUVR, the same pattern emerged: SUVRwas not associatedwithmean
RT or error rate, but higher SUVR predicted greater IIV, with a steeper
slope among Aβ-positive participants (supporting information).
Whole brain volume, WMHV, and APOE genotype showed no evi-
dence of associations with any outcome, although there was a trend
toward an association between larger whole brain volume and faster
RT (P< 0.1).
4 DISCUSSION
In this large population-based sample of adults aged ≈70 years, we
found that cognitively normal Aβ-positive participants showed greater
IIV in RT on a CRT task. To our knowledge, this has not been investi-
gatedbefore, but our results are consistentwith a previous report of an
association between CSF biomarkers of AD pathology and greater IIV
on a test of task-switching.39 We found no evidence that Aβ-positivity
was associatedwith slower RT. As expected, childhood cognitive ability




























amyloid negative amyloid positive
F IGURE 3 Intra-individual variability in reaction time for
cognitively normal amyloid-beta negative (n= 332) and amyloid-beta
positive (n= 74) participants. Points show the raw intra-individual
variability (IIV) values. Solid red lines represent the adjustedmeans
from themultivariate regressionmodel (adjusted for whole brain
volume, white matter hyperintensity volume, total intracranial
volume, apolipoprotein E genotype, sex, age at assessment, childhood
cognitive ability, education, and socioeconomic position), and the
dashed blue lines represent their 95% confidence intervals. IIV is
defined as the coefficient of variation (standard deviation/mean) for
correct responses.
and education showed some associations with performance, but there
was no evidence of the sex differences reported by others.10,16,19,23
Speed-accuracy trade-offs were identified as an important factor in
interpreting response patterns.
4.1 Speed-accuracy trade-offs
The most error-prone participants tended to have fast RTs, and the
slowest-responding participants tended to be highly accurate. Speed-
accuracy trade-offs in CRT tasks have been observed in some9 but
not all previous studies.40 We hypothesize that this difference may be
explained by the precise experimental design,with easier tasks (such as
ours and Nissan et al.9) being more susceptible to trade-offs, andmore
complex tasks (eg, Vaportzis et al.40) tending to show positive correla-
tions between speed and accuracy.
Within-subject speed-accuracy trade-offs were also observed (sup-
porting information), suggesting that errors tended to arise from hasty
or anticipatory responses. There was evidence that individuals altered
their speed-accuracy strategy during the task, slowing downaftermak-
ing an error.
4.2 Demographic and life-course predictors
4.2.1 Age at assessment
The finding that older age was associated with slower and more vari-
able RT is consistent with the literature.9-14 However, it is perhaps sur-
prising that this was seen in the Insight 46 cohort, because the age
range was so narrow (69.2 to 71.8 years—reflecting the length of the
data collection period, as participants were all born in the same week).
Estimates from previous studies suggest a slowing of 2.0 to 3.4 ms per
year across adulthood,11 or a decline of −0.096 SD per year.14 Our
effect size of 24 ms per year, or 0.30 SD, is large in comparison. This
result may in part reflect speed-accuracy trade-offs, as older age also
predicted lower error rate; this is consistent with evidence that older
people tend to respond more cautiously, prioritizing accuracy at the
expense of speed.41,42
We previously reported associations in Insight 46 between older
age and poorer non-verbal reasoning ability31 and smaller hippocam-
pal volumes.38 As discussed previously, we considered the possibil-
ity that such effects may be partially explained by a recruitment bias
whereby participants seen toward the beginning of the data collection
periodmayhavediffered in someways to those seen toward to the end.
However, we found no objective evidence of differences in health or
sociodemographic factors.
4.2.2 Childhood cognitive ability, education,
and socioeconomic position
Our results conform to previous analyses from the NSHD and
Insight 46, which have identified childhood cognitive ability and
education as key independent predictors of cognition across adult-
hood, whereas the effect of socioeconomic position is generally less
important.31,43
Consistent with extensive investigations into the relationship
between RT and general cognitive ability9,24-27 higher childhood cog-
nitive ability predicted faster RT more than 60 years later. This came
at no cost to accuracy, suggesting that participants with higher cogni-
tive ability may be better able to inhibit anticipatory responses. Con-
versely, educational attainment had no independent effect on RT and
error rate, but was independently associated with smaller IIV.
4.2.3 Sex differences
Contrary to some previous studies,10,16,23 in this large sample of nar-
row age range, and accounting for prior cognitive ability, there was
no evidence of sex differences on any CRT outcome, although subtle
effects may not be detectable over this small number of trials.
4.3 Associations with biomarkers
4.3.1 Aβ pathology
The mean difference in IIV between Aβ-positive and -negative par-
ticipants (10.3%; equivalent to 0.37 SD) was of a similar magni-
tude to their difference on a non-verbal reasoning test (0.39 SD),
and greater than on the Preclinical Alzheimer Cognitive Composite
(0.17 SD).31
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As Aβ-positive participants were all cognitively normal and more
than a decade away from the estimatedmedian age of onset of demen-
tia in the UK,44 this raises the possibility that IIV may be a particularly
sensitive measure of the cognitive consequences of accumulating AD
pathology, whereas the general slowing of RT may perhaps occur at a
later stage (as observed in individuals with MCI16,19-21). The associa-
tion between higher SUVR and greater IIV among Aβ-positive partici-
pants further supports the potential utility of this measure. Follow-up
assessments of Insight 46 participants (currently underway) will pro-
vide an opportunity to test this.
There was a suggestion that Aβ pathology was associated with
higher error rates, as Aβ-positive participants made more errors than
Aβ-negative participants and this difference was statistically signifi-
cant after adjustment for the trade-off between RT and error rate.
However, this finding needs to be interpreted with caution as this task
was limited in its ability to measure subtle differences in accuracy due
to the small number of trials (see section 4.4).
It is important to note that response speed and variability appear
to be general markers of the integrity of the central nervous sys-
tem, vulnerable to disruption across a range of neurodegenera-
tive diseases and brain injuries, correlating with diverse physical
health measures such as grip strength, forced expiratory volume, and
waist circumference,12,45,46 and potentially affected by many com-
mon medications.47 Performance of CRT tasks is also subserved by
multiple component executive processes including energizing, moni-
toring, and inhibiting.36 Further work is needed to investigate how
changes in RT associated with AD pathology may relate to physical
health measures and to other brain pathologies that accumulate with
age.
4.3.2 Brain volume and white matter disease
We previously reported that Insight 46 participants with smaller brain
volumesandgreaterburdenofwhitematterdiseasehad slightly slower
processing speedson theDigit-Symbol SubstitutionTest, a testwhich is
particularly sensitive tooverall brainhealth.31Wedidnot findevidence
of similar effects on CRT, although associations were in the expected
direction. As the detrimental effects of white matter disease on pro-
cessing speed and RT are well established,37,48,49 the lack of an associ-
ationbetweenWMHVandCRTmaybedue to the fact that participants
on the whole had very low levels of white matter disease.
4.4 Strengths and limitations
The CRT task typically took<3minutes to complete, making it feasible
for inclusion in a busy assessment schedule. However, the small num-
ber of trials limited the signal-noise ratio and had a particular impact
on the error ratemeasure, as a single incorrect response corresponded
to a large proportionate increase in error rate. It is worth noting that
many CRT studies place little focus on error rates, because RT is natu-
rally the primary interest. Our findings suggest that errors on this task
capturemeaningful differences between individuals and are also inher-
ently linked to differences in RT and IIV.
Strengths and limitations relating to the representativeness of
Insight 46participants havebeenpreviously discussed,31 themain limi-
tations being that all participants arewhite and the sample is inevitably
biased toward those in better health who are willing and able to travel
to London and to have a brain scan. The absence of PET or cere-
brospinal fluid measures of tau—limiting our ability to draw conclu-
sions about the pathological basis for alterations in RT performance—
will be addressed in future data collections.
4.5 Conclusions
In summary, this short CRT experiment provides novel evidence that
cognitively normal older adults with Aβ pathology are, on average, less
consistent in their response times. This builds on previous evidence
that Aβ pathology is associated with subtle changes in multiple cogni-
tive domains, even by age 70.
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